
via Wikipedia
A drug in development for obstructive sleep apnoea (OSA) has shown promising results, after researchers from Flinders University tested the treatment in people for the first time.
Designed to prevent the narrowing or collapse of the upper airways during sleep, a key factor in OSA, the treatment could prove to be a potential alternative for certain people with OSA to continuous positive airway pressure (CPAP) machines, which can only be tolerated by about half of all OSA sufferers.
“While further rigorous clinical evaluation and testing is required, this is a great first step and should offer some hope to the many people worldwide who suffer from sleep apnoea,” says study senior author Professor Danny Eckeart, Director of Flinders’ sleep lab FHMRI: Sleep Health.
“OSA is one of the most common sleep-related breathing disorders, with an estimated one billion sufferers, and when untreated is associated with major health and safety consequences. While CPAP machines are effective, tolerance remains a major issue for many and other treatments such as dental splints and upper airway surgery don’t always work. This is why we need new treatment options for OSA.
“At the moment, there are no approved drug treatments for OSA. However, with advances in our understanding of the different reasons people get OSA, the potential for effective new medications is growing stronger each year.”
Published in the journal Chest, the study tested the drug on 12 people with OSA using either nasal drops, a nasal spray or via direct application using an endoscope, versus a placebo.
Monitoring for sleep and airway activity across several sessions, the team found consistent and sustained improvements in the patients’ airways staying open throughout sleep, compared to the placebo treatment, regardless of the delivery method used.
“Although a small study, our findings represent the first detailed investigation of this new treatment in people with OSA, with promising results,” says study lead author Dr Amal Osman from FHMRI: Sleep Health.
“The drug we tested is designed to target specific receptors that are expressed on the surface of the upper airways, triggering them more easily to activate the surrounding muscles to keep the airway open during sleep. While there’s still a long way to go in terms of clinical testing and development, our study shows targeting these receptors may be a promising avenue for future treatments.”
Original Article: Could a nasal spray treat sleep apnea?
More from: Flinders University
The Latest Updates from Bing News
Go deeper with Bing News on:
Obstructive sleep apnoea
- 8 Warning Signs of Sleep Apnea
According to the American Medical Association, an estimated 30 million Americans have sleep apnea, yet only one-fifth of these are clinically diagnosed. For such a widespread condition, many people ...
- Sleep Better in Columbus: Don't ignore Sleep Apnea in Children and Teenagers
Dr. Adriana Davis says "Sleep apnea in children and teenagers is something that shouldn't be ignored." In the news: New research seems to be showing that teenagers with obstructive sleep apnea (OSA) ...
- Sleep apnea in adolescence may affect brain development
Teenagers with the nighttime breathing disorder sleep apnea may have brains that look a little different from their peers', a new study suggests.
- Sleep Apnea in Childhood Could Affect Developing Brain
Teenagers with the nighttime breathing disorder sleep apnea may have brains that look a little different from their peers', a new study suggests.
- Obstructive Sleep Apnea News
Mar. 9, 2022 — Obstructive sleep apnea (OSA) affects 22 million people in the U.S. and is linked to a higher risk of hypertension, heart attacks, stroke, diabetes and many other chronic conditions.
Go deeper with Bing News on:
Sleep apnea treatment
- 8 Warning Signs of Sleep Apnea
According to the American Medical Association, an estimated 30 million Americans have sleep apnea, yet only one-fifth of these are clinically diagnosed. For such a widespread condition, many people ...
- Nasdaq Congratulates Signifier Medical Technologies for Treating 10,000 Patients With eXciteOSA, a Daytime Therapy for Sleep Apnea
Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that eXciteOSA, the only FDA-authorized daytime therapy for sleep-disordered ...
- Sleep apnea in adolescence may affect brain development
Teenagers with the nighttime breathing disorder sleep apnea may have brains that look a little different from their peers', a new study suggests.
- Sleep apnea in childhood could affect developing brain
Teenagers with the nighttime breathing disorder sleep apnea may have brains that look a little different from their peers', a new study suggests.
- Sleep Disorders Treatment: Global Market Outlook
The report covers the market for sleep disorders treatment across different ... Different types of drugs are used to treat insomnia, sleep apnea, and other sleep disorder problems.Additionally ...